Teprotumumab shows promise in thyroid eye disease regardless of disease duration

Teprotumumab, an inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), has shown significant promise in treating thyroid eye disease (TED) regardless of the duration of the disease or the presence of active inflammation markers within the orbit, according to a recent review. Teprotumumab, initially approved for patients with recent-onset...